Clinical questions and uncertainty-prolactin measurement in patients with schizophrenia and bipolar disorder

Journal of Psychopharmacology

Volumn 22, Issue 2 SUPPL., 2008, Pages 82-89

  Walters, James ^a   Jones, Ian ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; PROLACTIN;

BIPOLAR DISORDER; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG MONITORING; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS; METABOLISM; METHODOLOGY; PATIENT SELECTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SECRETION;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DRUG MONITORING; HUMANS; HYPERPROLACTINEMIA; PATIENT SELECTION; PITUITARY GLAND; PROLACTIN; RISK ASSESSMENT; RISK FACTORS; SCHIZOPHRENIA;

EID: 51149104414     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881107086516     Document Type: Article

References (53)

1. Baturk M, Karaaslan F, Esel E, Sofuolu S, Tutu A, Yabanolu I (2001) Effects of short and long-term lithium treatment on serum prolactin levels in patients with bipolar affective disorder. Prog Neuro-Psychopharmacol Biol Psychiatry 25: 315-322
2. Boshes RA, Manschreck TC (2002) Review of antipsychotic medication administration: a proposal of intermittent dosing. Schizophr Bull 28: 203-222
3. Casey DE, Carson WH, Saha AR, Liebeskind A, Ali MW, Jody D, Ingenito GG. Aripiprazole Study Group (2003) Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacol 166: 391-399
4. Citrome L (2008) Current guidelines and their recommendations for prolactin monitoring in psychosis. J Psychopharmacol 22 (Suppl): 91-98
5. Crawford AMK, Beasley CM, Tollefson GD (1997) The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 26: 41-54
6. Das Gupta R, Guest JF (2002) Annual cost of bipolar disorder to UK society. Br J Psychiatry 180: 227-233
7. Davies LM, Drummond MF (1994) Economics and schizophrenia: the real cost. Brit J Psychiatry 165 (Suppl. 25): 18-21
8. Eberhard J, Lindstrom E, Holstad M, Levander S (2007) Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders. Acta Psychiatrica Scand 115: 268-276
9. Finn SE, Bailey JM, Schultz RT, Faber R (1990) Subjective utility ratings of neuroleptics in treating schizophrenia. Psychol Med 20: 843-848
10. Fitzgerald P, Dinan TG (2008) Prolactin and dopamine: What is the connection: A review article J Psychopharmacol 22 (Suppl): 12-19
11. Frye PE, Pariser SF, Kim MH, O'Shaughnessy RW (1982) Bromocriptine associated with symptom exacerbation during neuroleptic treatment of schizoaffective schizophrenia. J Clin Psychiatry 43: 252-253
12. Goode DJ, Meltzer HY, Fang VS (1980) Increased serum prolactin levels during phenothiazine and butyrophenone treatment of six postpartum women. Psychoneuroendocrinol 5: 345-351
13. Haddad PM, Wieck A (2004) Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64: 2291-2314
14. Halbreich U, Kinon BJ, Gilmore JA, Kahn LS (2003) Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinol 28 (Suppl. 1): 53-67
15. Harvey PW, Everett DJ, Springall CJ (2008) Adverse effects of prolactin in rodents and humans: Breast and prostate cancer. J Psychopharmacol 22 (Suppl): 20-27
16. Heinrichs DW, Hanlon TE, Carpenter WT (1984) The quality of life scale - an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 10: 388-398
17. Hellewell JSE, Cantillon M (1998) Antipsychotic tolerability: the attitudes and perceptions of medical professionals, patients and caregivers towards the side effects of antipsychotic therapy. Eur Neuropsychopharmacol 8 (Suppl. 2): 248
18. Holt RIG (2008) Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists. J Psychopharmacol 22 (Suppl): 28-37
19. Holt RIG, Javaid MK (2008) Understanding osteoporosis J Psychopharmacol 22 (Suppl): 38-45
20. Howes OD, Smith S, Gaughran FP, Amiel SA, Murray RM, Pilowsky LS (2006) The relationship between prolactin levels and glucose homeostasis in antipsychotic-treated schizophrenic patients. J Clin Psychopharmacol 26: 629-631
21. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW (2006) Randomized controlled trial of the effect on Quality of Life of second-vs firstgeneration antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63: 1079-1087
22. Kapur S, Langlois X, Vinken P, Megens AAHP, De Coster R, Andrews JS (2002) The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Therap 302: 1129-1134
23. Kapur S, Seeman P (2001) Does fast dissociation from the dopamine d (2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 158: 360-369
24. Keks NA, Copolov DL, Singh BS (1987) Abnormal prolactin response to haloperidol challenge in men with schizophrenia. Am J Psychiatry 144: 1335-1337
25. Kim K-S, Pae C-U, Chae J-H, Bahk W-M, Jun T-Y, Kim D-J, Dickson RA (2002) Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry 63: 408-413
26. Kinon BJ, Ahl J, Liu-Seifert H, Maguire GA (2006) Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinol 31: 577-588
27. Kinon BJ, Gilmore JA, Liu H, Halbreich UM (2003) Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinol 28 (Suppl. 2): 55-68
28. Kleinberg DL, Davis JM, de Coster R, Van Baelen B, Brecher M (1999) Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 19: 57-61
29. Knapp M (1997) Costs of schizophrenia. Brit J Psychiatry 171: 509-518
30. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) The clinical antipsychotic trials of intervention effectiveness I. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223
31. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S (2004) Physical health monitoring of patients with schizophrenia. Am J Psychiatry 161: 1334-1349
32. Matsuoka I, Nakai T, Miyake M, Hirai M, Ikawa G (1986) Effects of bromocriptine on neuroleptic-induced amenorrhea, galactorrhea and impotence. Jap J Psychiatry Neurol 40: 639-646
33. Melkersson KI (2006) Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Human Psychopharmacol 21: 529-532
34. Meltzer HY, Fang VS (1976) The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psych 33: 279-286
35. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC (2007) Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 64: 543-552
36. Murray CJL, Lopez AD (1997) Global mortality, disability and the contribution of risk factors: global burden of disease study. Lancet 349: 1436-1442
37. Nemeroff CB, Kinkead B, Goldstein J (2002) Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry 63 (Suppl. 13): 5-11
38. NICE (2006) Bipolar disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. NICE guidelines July 2006
39. O'Keane V (2008) Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol 22 (Suppl): 70-75
40. Perala J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsa E, Pirkola S, Partonen T, Tuulio-Henriksson A, Hintikka J, Kieseppa T, Harkanen T, Koskinen S, Lonnqvist J (2007) Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psych 64: 19-28
41. Perovich RM, Lieberman JA, Fleischhacker WW, Alvir J (1989) The behavioral toxicity of bromocriptine in patients with psychiatric illness. J Clin Psychopharmacol 9: 417-422
42. Pollock A, McLaren EH (1998) Serum prolactin concentration in patients taking neuroleptic drugs. Clin Endocrinol 49: 513-516
43. Rao ML, Gross G, Strebel B, Halaris A, Huber G, Braunig P, Marler M (1994) Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia. Biol Psychiatry 35: 151-163
44. Smith S (1992) Neuroleptic-associated hyperprolactinemia. Can it be treated with bromocriptine? J Repro Med 37: 737-740
45. Smith S (2003) Effects of antipsychotics on sexual and endocrine function in women: implications for clinical practice. J Clin Psychopharmacol 23 (Suppl. 1) : 27-32
46. Smith S, Wheeler MJ, Murray R, O'Keane V (2002) The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamicpituitary-gonadal axis. J Clin Psychopharmacol 22: 109-114
47. Smith S (2008) The impact of hyperprolactinaemia on sexual function in patients with psychosis. J Psychopharmacol 22 (Suppl.): 63-69
48. Takahashi H, Higuchi H, Kamata M, Naitoh S, Yoshida K, Shimizu T, Sugita T (2003) Effectiveness of switching to quetiapine for neuroleptic-induced amenorrhea. J Neuropsych Clin Neurosci 15: 375-377
49. Wieck A, Haddad PM (2003) Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review. Brit J Psychiatry 182: 199-204
50. Windgassen K, Wesselmann U, Schulze Monking H (1996) Galactorrhea and hyperprolactinemia in schizophrenic patients on neuroleptics: frequency and etiology. Neuropsychobiol 33: 142-146
51. Wistedt B, Wiles D, Kolakowska T (1981) Slow decline of plasma drug and prolactin levels after discontinuation of chronic treatment with depot neuroleptics. Lancet 1: 1163
52. Wudarsky M, Nicolson R, Hamburger SD, Spechler L, Gochman P, Bedwell J, Lenane MC, Rapoport JL (1999) Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolescent Psychopharmacol 9: 239-245
53. Yusufi BZ, Mukherjee S, Aitchison K, Dunn G, Page E, Barnes TR (2005) Inter-rater reliability of the antipsychotic non-neurological side-effects rating scale (ANNSERS). Schizophr Bull 31: 574